The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SITC 2021 | Mechanism of action of GTB-3550 TriKE
Jeffrey S. Miller, MD, University of Minnesota, Minneapolis, MN, discusses the mechanism of action and rationale behind the development of GTB-3550, a tri-specific killer engager (TriKE®) for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.
